India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
‘Emotional Loneliness’ Among Parents With Children Abroad Kathmandu Metropolitan City has reported that emotional loneliness is beginning to be seen among senior citizens with children abroad. A survey conducted by the metropolis has found emotional loneliness among senior citizens with children. This situation has been shown by a study conducted by Prahlad Adhikari on the topic of ‘The Responsibility of the Metropolitan City for the Mental Health of Senior Citizens’ in the third edition of the Metropolitan Research Fellowship (MRF). Binita Adhikari was the supervisor of the study. According to the study, 21.7 percent of people have been found to have severe and very severe emotional loneliness. The Metropolitan City survey found that 62.3 percent had moderate loneliness. Similarly, 15 percent did not experience any kind of emotional loneliness. Similarly, from the perspective of social loneliness, 48 percent had high loneliness, 28.3 percent had moderate loneliness, and 23.7 pe...